Ruxolitinib Vs Prednisone As First-line Therapy for CGVHD Needing Systemic Therapy

Phase 2

Not yet recruiting

• Conditions: Chronic Graft-versus-host Disease (cGVHD)
• Interventions: Drug: Ruxolitinib; Drug: Prednisone

• Registration Number: NCT06660355
• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Brief Summary

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of therapy based on a prior large, randomized phase III study. Given this evidence of safety and efficacy in the early refractory setting...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2024-10
• Study First Submitted: 2024-10-24
• Study First Submitted QC: 2024-10-24
• Last Update Submitted: 2024-10-24
• Study First Posted: 2024-10-28
• Last Update Posted: 2024-10-28
• Study Start: 2024-11
• Primary Completion: 2028-11
• Study Completion: 2028-11

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Age ≥ 18 years.

• Karnofsky performance status ≥60%.

• Patients with a diagnosis of chronic GVHD per NIH diagnostic criteria5 who are in need for first systemic therapy as per treating physician's discretion, Overlap chronic GVHD will be allowed.

• No new immune suppressive therapy added within preceding 2 weeks prior to study enrolment.

• Able to take oral medications.

• Participants must have adequate organ and marrow function as defined below:

  1. absolute neutrophil count ≥1,000/mcL
  2. platelets ≥30,000/mcL
  3. Hemoglobin ≥ 7 g/dL
  4. Bilirubin ≤ 3 times institutional upper limit of normal (ULN) unless attributable to GVH

  d. AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN unless attributable to GVH e. creatinine clearance ≥30 ml/min

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration.

• Ability to understand and the willingness to sign a written informed consent document.

Read More

Exclusion Criteria

• Previously treated with systemic immune suppressive therapy for chronic GVHD (where the indication for start of that systemic immune suppressive therapy was chronic GVHD).
• Patients with clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction, or stroke within 6 months, New York Heart Association class III or IV heart failure will be excluded.
• Relapse malignancy post- transplant.
• Active hepatitis B, hepatitis C and HIV will be excluded.
• Any uncontrolled infection at the time if enrollment will be excluded.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ruxolitinib.
• Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women and lactating women are excluded from this study because of the potential for teratogenic or abortifacient effects and an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Ruxolitinib, breastfeeding should be discontinued if the mother is treated with Ruxolitinib.
• Current or history of active Tuberculosis.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ruxolitinib Treatment Arm	Ruxolitinib	Ruxolitinib is administered as 10 mg orally twice daily in 28-day cycles.
Prednisone Treatment Arm	Prednisone	Prednisone will be started at 1mg/kg/day based on patient current body weight in kilograms.

Primary Outcome Measures

Name	Time	Method
Treatment Success	6 months	Treatment Success is defined as C7D1 NIH CR/PR without death or new line of immune suppressive therapy and will be estimated for both arms.

Secondary Outcome Measures

Name	Time	Method
Treatment Success Rate	6 months	The proportion of subjects who are alive with NIH CR/PR, no new systemic therapy for cGVHD, and \< 0.25 mg/kg/day prednisone at C7D1 with 95% CI for each arm will be estimated.

Trial Locations

Locations (1)

Moffitt Cancer Center; 🇺🇸 Tampa, Florida, United States